Atea Pharmaceuticals
AVIR
127 hedge funds and large institutions have $323M invested in Atea Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 39 increasing their positions, 38 reducing their positions, and 10 closing their positions.
170% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 10
59% more capital invested
Capital invested by funds: $203M → $323M (+$119M)
14% more funds holding
Funds holding: 111 → 127 (+16)
2.47% more ownership
Funds ownership: 72.96% → 75.43% (+2.5%)
3% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 38
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$10.4M |
| 2 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
+$5.38M |
| 3 |
Two Sigma Investments
New York
|
+$5.14M |
| 4 |
ICM
Irenic Capital Management
New York
|
+$1.39M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$1.98M |
| 2 |
JP Morgan Chase
New York
|
-$1.87M |
| 3 |
Millennium Management
New York
|
-$1.6M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$853K |
| 5 |
PLC
Peapod Lane Capital
Bedford Hills,
New York
|
-$745K |
AVIR Hedge Fund Activity: Q1 2026 in Review
127 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Atea Pharmaceuticals (AVIR) for Q1 2026, worth a combined $323M — up 59% from $203M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new AVIR positions and 10 closed out — a net gain of 17 holders — while 39 added to existing stakes and 38 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $10.4M. The largest seller was BML Capital Management, cutting an estimated $1.98M.
- 127 institutional investors held Atea Pharmaceuticals (AVIR) as of Q1 2026, up from 111 in Q4 2025.
- Funds reported $323M of Atea Pharmaceuticals stock for Q1 2026, up 59% quarter-over-quarter.
- 27 funds opened new Atea Pharmaceuticals positions in Q1 2026 and 10 closed out, a net change of +17 holders.
- The largest Atea Pharmaceuticals buyer in Q1 2026 was Fidelity Investments, an estimated $10.4M added.
- The largest Atea Pharmaceuticals seller in Q1 2026 was BML Capital Management, an estimated $1.98M sold.
Based on aggregated 13F filings for Q1 2026.